Overview of clinical lung transplantation

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 1, 2014, Pages

  Yeung, Jonathan C ^a   Keshavjee, Shaf ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEART DEATH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG INJURY; LUNG TRANSPLANTATION; ORGAN DONOR; ORGAN PRESERVATION; POSTOPERATIVE CARE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RESPIRATORY FAILURE; SURGICAL TECHNIQUE; SURVIVAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; DONOR SELECTION; DRUG CONTRAINDICATION; GRAFT REJECTION; HEALTH CARE ORGANIZATION; LUNG DISEASE; METHODOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; TRANSPLANTATION;

DONOR SELECTION; GRAFT REJECTION; HEALTH CARE RATIONING; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; ORGAN PRESERVATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 84891782989     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a015628     Document Type: Article

References (108)

1. Alessandrini F., D'Armini AM, Roberts CS, Reddick RL, Egan TM. 1994. When does the lung die? II. Ultrastructural evidence of pulmonary viability after "death. " J Heart Lung Transplant 13: 748-757.
2. Ardehali A., Laks H, Levine M, Shpiner R, Ross D, Watson LD, ShvartzO, Sangwan S, Waters PF. 2001. A prospective trial of inhaled nitric oxide in clinical lung transplantation. Transplantation 72: 112-115.
3. Benden C., Edwards LB, Kucheryavaya AY, Christie JD, Dipchand A.I., Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz M.I., et al. 2013. The registry of the International Society for Heart and Lung Transplantation: Fifteenth pediatric lung and heart-lung transplantation report-2012. J Heart Lung Transplant 31: 1087-1095.
4. Boasquevisque C.H., Yildirim E, Waddel TK, Keshavjee S. 2009. Surgical techniques: Lung transplant and lung volume reduction. Proc Am Thorac Soc 6: 66-78.
5. Botha P., Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, Gould K, Fisher AJ. 2008. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 85: 771-774.
6. Burlingham W.J., Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, Braun RK, Greenspan D.S., et al. 2007. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 117: 3498-3506.
7. Butt T.A., Aitchison JD, Corris PA, Wardle J, Clark S, Dark JH. 2007. 140: Lung transplantation from deceased donors without pretreatment. J Heart Lung Transplant 26: S110.
8. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. 1978. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323-1327.
9. Chaparro C., Maurer J, Gutierrez C, Krajden M, Chan C, Winton T., Keshavjee S, Scavuzzo M, Tullis E, Hutcheon M, et al. 2001. Infection with Burkholderia cepacia in cystic fibrosis: Outcome following lung transplantation. Am J Respir Crit Care Med 163: 43-48.
10. Christie J.D., Carby M, Bag R, Corris P, Hertz M, Weill D. 2005. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 24: 1454-1459.
11. Christie J.D., Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. 2010. The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 29: 1104-1118.
12. Christie J.D., Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI, et al. 2012. The Registry of the International Society for Heart and Lung Transplantation: 29th Adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 31: 1073-1086.
13. Coggins M.P., Bloch KD. 2007. Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol 27: 1877-1885.
14. Cohen L., Littlefield C, Kelly P, Maurer J, Abbey S. 1998. Predictors of quality of life and adjustment after lung transplantation. Chest 113: 633-644.
15. Colvin-Adams M, Valapour M, Hertz M, Heubner B, Paulson K, Dhungel V, Skeans MA, Edwards L, Ghimire V, Waller C., et al. 2012. Lung and heart allocation in the United States. Am J Transplant 12: 3213-3234.
16. Cooper J.D., Pearson FG, Patterson GA, Todd TR, Ginsberg RJ, Goldberg M, DeMajo WA. 1987. Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg 93: 173-181.
17. Couetil J.P., Tolan MJ, Loulmet DF, Guinvarch A, Chevalier PG, Achkar A, Birmbaum P, Carpentier AF. 1997. Pulmonary bipartitioning and lobar transplantation: A new approach to donor organ shortage. J Thorac Cardiovasc Surg 113: 529-537.
18. Cypel M., Keshavjee S. 2012. Extracorporeal membrane oxygenation as a bridge to lung transplantation. ASAIO J 58: 441-442.
19. Cypel M., Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M., Sato M, Harwood S, Pierre A, Waddell TK, et al. 2008. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 27: 1319-1325.
20. Cypel M., Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, Sato M, Medin J, Davidson BL, de Perrot M, et al. 2009. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 1: 4ra9.
21. Cypel M., Yeung JC, Liu M, Anraku M, Chen F, Karolak W, Sato M., Laratta J, Azad S, Madonik M, et al. 2011. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 364: 1431-1440.
22. Cypel M., Yeung JC, Machuca T, Chen M, Singer LG, Yasufuku K, de Perrot M, Pierre A, Waddell TK, Keshavjee S. 2012. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg 144: 1200-1206.
23. D'Armini AM, Roberts CS, Griffith PK, Lemasters JJ, Egan TM. 1994. When does the lung die? I. Histochemical evidence of pulmonary viability after "death. " J Heart Lung Transplant 13: 741-747.
24. Date H., Matsumura A, Manchester JK, Cooper JM, Lowry OH, Cooper JD. 1993. Changes in alveolar oxygen and carbon dioxide concentration and oxygen consumption during lung preservation. The maintenance of aerobic metabolism during lung preservation. J Thorac Cardiovasc Surg 105: 492-501.
25. Date H., Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA. 1996. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 111: 913-919.
26. Date H., Aoe M, Sano Y, Nagahiro I, Miyaji K, Goto K, Kawada M., Sano S, Shimizu N. 2004. Improved survival after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg 128: 933-940.
27. Davis RD Jr, Lau CL, Eubanks S, Messier RH, Jadjiliadis D, Steele M.P., Palmer SM. 2003. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 125: 533-542.
28. de Hoyos A, DemajoW, Snell G, Miller J, Winton T, Maurer JR, Patterson GA. 1993. Preoperative prediction for the use of cardiopulmonary bypass in lung transplantation. J Thorac Cardiovasc Surg 106: 787-795.
29. de Perrot M, Fischer S, Liu M, Jin R, Bai XH, Waddell TK, Keshavjee S. 2001. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: A shift from pro-to anti-inflammatory cytokines. Transplantation 72: 1505-1512.
30. de Perrot M, Liu M, Waddell TK, Keshavjee S. 2003. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 167: 490-511.
31. de Perrot M, Granton JT, McRae K, Cypel M, Pierre A, Waddell T.K., Yasufuku K, Hutcheon M, Chaparro C, Singer L., et al. 2011. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. J Heart Lung Transplant 30: 997-1002.
32. Derom F., Barbier F, Ringoir S, Versieck J, Rolly G, Berzsenyi G, Vermeire P, Vrints L. 1971. Ten-month survival after lung homotransplantation in man. J Thorac Cardiovasc Surg 61: 835-846.
33. Egan TM. 2004. Non-heart-beating donors in thoracic transplantation. J Heart Lung Transplant 23: 3-10.
34. Egan T.M., Lambert CJ Jr, Reddick R, Ulicny KS Jr, Keagy BA, Wilcox BR. 1991. A strategy to increase the donor pool: Use of cadaver lungs for transplantation. Ann Thorac Surg 52: 1113-1120.
35. Egan TM, Murray S, Bustami RT, Shearon TH, McCullough KP, Edwards LB, Coke MA, Garrity ER, Sweet SC, Heiney DA, et al. 2006. Development of the new lung allocation system in the United States. Am J Transplant 6: 1212-1227.
36. Erasmus M.E., van der BijW, Verschuuren EAM. 2006. Nonheart-beating lung donation in theNetherlands: The first experience. J Heart Lung Transplant 25: S63.
37. Fischer S., Simon AR, Welte T, Hoeper MM, Meyer A, Tessmann R, Gohrbandt B, Gottlieb J, Haverich A, Strueber M. 2006. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg 131: 719-723.
38. Fischer S., Bohn D, Rycus P, Pierre AF, de Perrot M, Waddell TK, Keshavjee S. 2007. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: Analysis of the Extracorporeal Life Support Organization (ELSO) registry. J Heart Lung Transplant 26: 472-477.
39. Fiser S.M., Kron IL, McLendon Long S, Kaza AK, Kern JA, Tribble CG. 2001. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant 20: 631-636.
40. Follette D.M., Rudich SM, Babcock WD. 1998. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 17: 423-429.
41. Garcia J.P., Kon ZN, Evans C, Wu Z, Iacono AT, McCormick B, Griffith BP. 2011. Ambulatory veno-venous extracorporeal membrane oxygenation: Innovation and pitfalls. J Thorac Cardiovasc Surg 142: 755-761.
42. Gilljam M., Schersten H, Silverborn M, Jonsson B, Ericsson Hollsing A. 2010. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 9: 272-276.
43. Goers T.A., Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. 2008. De novo production of K-α1 tubulin-specific antibodies: Role in chronic lung allograft rejection. J Immunol 180: 4487-4494.
44. Goldberg M., LimaO, Morgan E, Ayabe HA, Luk S, Ferdman A, Peters WJ, Cooper JD. 1983. A comparison between cyclosporin A and methylprednisolone plus azathioprine on bronchial healing following canine lung autotransplantation. J Thorac Cardiovasc Surg 85: 821-826.
45. Grasemann H., de Perrot M, Bendiak GN, Cox P, van Arsdell GS, Keshavjee S, Solomon M. 2012. ABO-incompatible lung transplantation in an infant. Am J Transplant 12: 779-781.
46. Griffith B.P., Magee MJ, Gonzalez IF, Houel R, Armitage JM, Hardesty R.L., Hattler BG, Ferson PF, Landreneau RJ, Keenan RJ. 1994. Anastomotic pitfalls in lung transplantation. J Thorac Cardiovasc Surg 107: 743-753.
47. Gross C.R., Savik K, Bolman RM III, Hertz MI. 1995. Longterm health status and quality of life outcomes of lung transplant recipients. Chest 108: 1587-1593.
48. Hachem R.R., Edwards LB, Yusen RD, Chakinala MM, Alexander Patterson G., Trulock EP. 2008. The impact of induction on survival after lung transplantation: An analysis of the International Society for Heart and Lung Transplantation Registry. Clin Transplant 22: 603-608.
49. Haglin J., Telander RL, Muzzall RE, Kiser JC, Strobel CJ. 1963. Comparison of lung autotransplantation in the primate and dog. Surg Forum 14: 196-198.
50. Hardy J.D., Webb WR, Dalton ML Jr, Walker GR Jr. 1963. Lung homotransplantation in man. JAMA 186: 1065-1074.
51. Hartwig M.G., Snyder LD, Appel JZ II, Cantu E III, Lin SS, Palmer S.M., DavisRD. 2008. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 27: 547-553.
52. Helmi M., Love RB, WelterD, Cornwell RD, Meyer KC. 2003. Aspergillus infection in lung transplant recipients with cystic fibrosis: Risk factors and outcomes comparison to other types of transplant recipients. Chest 123: 800-808.
53. Iribarne A., Russo MJ, Davies RR, Hong KN, Gelijns AC, Bacchetta M.D., D'Ovidio F, Arcasoy S, Sonett JR. 2009. Despite decreased wait-list times for lung transplantation, lung allocation scores continue to increase. Chest 135: 923-928.
54. Keshavjee S.H., Yamazaki F, Cardoso PF, McRitchie DI, Patterson GA, Cooper JD. 1989. A method for safe twelvehour pulmonary preservation. J Thorac Cardiovasc Surg 98: 529-534.
55. Keshavjee S.H., Yamazaki F, Yokomise H, Cardoso PF, Mullen JB, Slutsky AS, Patterson GA. 1992. The role of dextran 40 and potassium in extended hypothermic lung preservation for transplantation. J Thorac Cardiovasc Surg 103: 314-325.
56. Kootstra G., Daemen JH, Oomen AP. 1995. Categories of non-heart-beating donors. Transplant Proc 27: 2893-2894.
57. Kootstra G., Kievit J, Nederstigt A. 2002. Organ donors: Heartbeating and non-heartbeating. World J Surg 26: 181-184.
58. Langer RM. 2011. Vladimir P. Demikhov, a pioneer of organ transplantation. Transplant Proc 43: 1221-1222.
59. Lanuza D.M., Lefaiver C, McCabe M, Farcas GA, Garrity E Jr, 2000. Prospective study of functional status and quality of life before and after lung transplantation. Chest 118: 115-122.
60. Lopau K., Mark J, Schramm L, Heidbreder E, Wanner C. 2000. Hormonal changes in brain death and immune activation in the donor. Transpl Int 13: S282-S285.
61. Lozano R., Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V., Abraham J, Adair T, Aggarwal R, Ahn SY, et al. 2013. Global and regional mortality from235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128.
62. Machuca T.N., Keshavjee S. 2012. Transplantation for lung cancer. Curr Opin Organ Transplant 17: 479-484.
63. Mason DP, Murthy SC, Gonzalez-StawinskiGV, BudevMM, Mehta A.C., McNeill AM, Pettersson GB. 2008. Early experience with lung transplantation using donors after cardiac death. J Heart Lung Transplant 27: 561-563.
64. Metras H. 1950. Note preliminarie sur la greffe total du poumon chez le chien. CR Acad Sci III 231: 1176-1177.
65. Murphy D.M., Forrest IA, Corris PA, Johnson GE, Small T, Jones D., Fisher AJ, Egan JJ, Cawston TE, Lordan JL, et al. 2008. Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. J Heart Lung Transplant 27: 1210-1216.
66. Murray S., Charbeneau J, Marshall BC, LiPuma JJ. 2008. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 178: 363-371.
67. National Data. 2012. http://www.unos.org/data/about/ viewDataReports.asp (accessed January 2, 2013).
68. Noirclerc M., Shennib H, Giudicelli R, Latter D, Metras D, Colt H.G., Mulder D. 1992. Size matching in lung transplantation. J Heart Lung Transplant 11: S203-S208.
69. Orens J.B., Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S., Kotloff R, Morton J, Studer SM, Van Raemdonck D, et al. 2003. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 22: 1183-1200.
70. Orens J.B., Estenne M, Arcasoy S, Cont JV, Corris P, Egan JJ, Egan T., Keshavjee S, Knoop C, Kotloff R, et al. 2006. International guidelines for the selection of lung transplant candidates: 2006 update-A consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25: 745-755.
71. Oto T., Levvey B, McEgan R, Davies A, Pilcher D, Williams T, Marasco S., Rosenfeldt F, Snell G. 2007. A practical approach to clinical lung transplantation from a Maastricht Category III donor with cardiac death. J Heart Lung Transplant 26: 196-199.
72. Pakhale S.S., HadjiliadisD, Howell DN, Palmer SM, Gutierrez C, Waddell TK, Chaparro C, Davis RD, Keshavjee S, Hutcheon M.A., et al. 2005. Upper lobe fibrosis: A novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant 24: 1260-1368.
73. Palmer S.M., Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen N.L., Schwartz DA. 2005. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 171: 780-785.
74. Patel V.S., Palmer SM, Messier RH, Davis RD. 2003. Clinical outcome after coronary artery revascularization and lung transplantation. Ann Thorac Surg 75: 372-377.
75. Patterson G.A., Cooper JD, Goldman B, Weisel RD, Pearson FG, Waters PF, Todd TR, Scully H, Goldberg M, Ginsberg RJ. 1988. Technique of successful clinical double-lung transplantation. Ann Thorac Surg 45: 626-633.
76. Pilcher D.V., Scheinkestel CD, Snell GI, Davey-Quinn A, Bailey MJ, Williams TJ. 2005. High central venous pressure is associated with prolonged mechanical ventilation and increased mortality after lung transplantation. J Thorac Cardiovasc Surg 129: 912-918.
77. Reitz B.A., Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE, Stinson EB, Shumway NE. 1982. Heart-lung transplantation: Successful therapy for patients with pulmonary vascular disease. N Engl JMed 306: 557-564.
78. Sánchez-Fructuoso AI, PratsD, Torrente J, Pérez-ContínMJ, Fernández C, Alvarez J, Barrientos A. 2000. Renal transplantation from non-heart beating donors: A promising alternative to enlarge the donor pool. J Am Soc Nephrol 11: 328-350.
79. Sato M. 2013. Chronic lung allograft dysfunction after lung transplantation: The moving target. Gen Thorac Cardiovasc Surg 61: 67-78.
80. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, WagnetzD, Chaparro C, Singer LG, Hutcheon MA, et al. 2011. Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 30: 735-742.
81. Sato M., Hwang DM, Waddell TK, Singer LG, Keshavjee S. 2013. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant 32: 23-30.
82. Snyder L.D., Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner D.A., Palmer SM. 2010. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 181: 1391-1396.
83. Starnes V.A., Barr ML, Cohen RG. 1994. Lobar transplantation. Indications, technique, and outcome. J Thorac Cardiovasc Surg 108: 403-410.
84. Starzl T.E., Klintmalm GB, Porter KA, Iwatsuki S, Schroter GP. 1981. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med 305: 266-269.
85. Steinbrook R. 2007. Organ donation after cardiac death. N Engl J Med 357: 209-213.
86. Strueber M., Hoeper MM, Fischer S, Cypel M, Warnecke G, Gottlieb J., Pierre A, Welte T, Haverich A, Simon AR, et al. 2009. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am J Transplant 9: 853-857.
87. Studer S.M., Levy RD, McNeil K, Orens JB. 2004. Lung transplant outcomes: A review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 24: 674-685.
88. Sweet SC. 2009. Update on pediatric lung allocation in the United States. Pediatr Transplant 13: 808-813.
89. Taghavi S., Bîrsan T, Pereszlenyi A, Kupilik N, Deviatko E, Wisser W., Steltzer H, Klepetko W. 1999. Bilateral lung transplantation via two sequential anterolateral thoracotomies. Eur J Cardiothorac Surg 15: 658-662.
90. Takada M., Nadeau KC, HancockWW, Mackenzie HS, Shaw GD, Waaga AM, Chandraker A, Sayegh MH, Tilney NL. 1998. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 65: 1533-1542.
91. Thabut G., Christie JD, Ravaud P, Castier Y, Brugière O, Fournier M, Mal H, Lesèche G, Porcher R. 2008. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: A retrospective analysis of registry data. Lancet 371: 744-751.
92. Ulicny KS Jr, Egan TM, Lambert CJ Jr, Reddick RL, Wilcox BR. 1993. Cadaver lung donors: Effect of preharvest ventilation on graft function. Ann Thorac Surg 55: 1185-1191.
93. Vanaudenaerde B.M., Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM. 2008. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 32: 832-843.
94. Van De Wauwer C, Neyrinck AP, Geudens N, Rega FR, Verleden GM, Verbeken E, Lerut TE, Van Raemdonck DE. 2009. Retrograde flush following warm ischemia in the non-heart-beating donor results in superior graft performance at reperfusion. J Surg Res 154: 118-125.
95. Van Raemdonck DE, Jannis NC, Rega FR, De Leyn PR, Flameng W.J., Lerut TE. 1997. Extended preservation of ischemic pulmonary graft by postmortem alveolar expansion. Ann Thorac Surg 64: 801-808.
96. Van Raemdonck DE, Rega FR, Neyrinck AP, Jannis N, Verleden GM, Lerut TE. 2004. Non-heart-beating donors. Semin Thorac Cardiovasc Surg 16: 309-321.
97. Van Raemdonck D, Verleden GM, Dupont L, Ysebaert D, Monbaliu D, Neyrinck A, CoosemansW, Decaluwe H, De Lyn P., Nafteux P, et al. 2008. Initial experience with lung transplantation from non-heart-beating donors. J Heart Lung Transplant 27: S198-S199.
98. Varela A., Cordoba M, Serrano-Fiz S, Burgos R, Montero CG, Téllez G, Novoa N, Castedo E, Tebar E, Téllez J, et al. 1997. Early lung allograft function after retrograde and antegrade preservation. J Thorac Cardiovasc Surg 114: 1119-1120.
99. Venkateswaran R.V., Patchell VB, Wilson IC, Mascaro JG, Thompson R.D., Quinn DW, Stockley RA, Coote JH, Bonser RS. 2008. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 85: 278-286.
100. Vos R., Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, Schoonis A, Nawrot TS, Dupont LJ, Verleden GM. 2011. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 37: 164-172.
101. Wang D., Zhou X, Liu X, Sidor B, Lynch J, Zwischenberger JB. 2008. Wang-Zwische double lumen cannula-Toward a percutaneous and ambulatory paracorporeal artificial lung. ASAIO J 54: 606-611.
102. Weiss E.S., Allen JG, Merlo CA, Conte JV, Shah AS. 2009. Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis. Ann Thorac Surg 88: 1616-1625.
103. Wells A., Faro A. 2006. Special considerations in pediatric lung transplantation. Semin Respir Crit Care Med 27: 552-560.
104. Whitson BA, Nath DS, JohnsonAC, Walker AR, Prekker ME, Radosevich D.M., Herrington CS, Dahlberg PS. 2006. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 131: 73-80.
105. Wigfield C.H., Cypel M, Yeung J, Waddell T, Alex C, Johnson C, Keshavjee S, Love RB. 2012. Successful emergent lung transplantation after remote ex vivo perfusion optimization and transportation of donor lungs. Am J Transplant 12: 2838-2844.
106. Wijdicks E.F., Varelas PN, Gronseth GS, Greer DM. 2010. Evidence-based guideline update: Determining brain death in adults: Report of theQuality Standards Subcommittee of the AmericanAcademy ofNeurology. Neurology 74: 1911-1918.
107. Yates B., Murphy DM, Forrest IA, Ward C, Rutherford Rm, Fisher A.J., Lordan JL, Dark JH, Corris PA. 2005. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 172: 772-775.
108. Yeung JC, Wagnetz D, Cypel M, Rubacha M, Koike T, Chun YM, Hu J, Waddell TK, Hwang DM, Liu M, et al. 2012. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre-and postlung transplantation in the pig. Mol Ther 20: 1204-1211.